Drug Trial Radar · NCT07930637
Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Sinfatin S.LIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of the study is to assess the effect of rimonabant in cognitive performance in patients with Post-COVID-19 Syndrome, also known as long COVID. The study will include 80 adults aged 18 to 75 years that will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given. The study will also help to learn about the safety of rimonabant.
Conditions
- Post-COVID-19 Syndrome
Interventions
RimonabantDrug
Rimonabant 2.5 mg tablets. Two tablets are taken together orally once a day in fasted conditions, providing a total daily dose of 5 mg. Treatment duration is 90 days.
PlaceboDrug
Placebo tablets matching the appearance of the rimonabant tablets. Two tablets are taken together orally once daily in fasted conditions. Treatment duration is 90 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symbol Digit Modalities Test (SDMT)Time frame: Baseline to end of follow-up (day 135)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario de Albacete
Albacete, Spain
Hospital Clinica San Carlos HCSC
Madrid, Spain
Hospital Nacional de Paraplejicos
Toledo, Spain
Athenea Neuroclinics
San Sebastián, Donostia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.